Company to Host Conference Call and Webcast
on May 8, 2024
LOS
ANGELES, May 1, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision
oncology company focused on developing and commercializing
therapies for cancers with alterations in the mTOR pathway, today
announced that it will host a conference call and live webcast
on Wednesday, May 8, 2024 at 8:30 am
EDT (5:30 am PDT) to report
first quarter 2024 financial results and provide recent corporate
updates.
Conference Call Information
Participants may access a live webcast of the call on the
"Investors & News" page of the Aadi
Bioscience website at aadibio.com. To participate via
telephone, please register in advance here: Conference
Registration (vevent.com). Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. A replay of the conference call and webcast will be archived
on the website for at least 30 days.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage precision oncology company focused on
the development and commercialization of therapies for cancers with
alterations in the mTOR pathway, a key regulator of cell growth and
cancer progression. To unlock the full potential of mTOR
inhibition, Aadi uniquely combines nanoparticle albumin-bound
(nab) technology with the potent mTOR inhibitor, sirolimus.
Aadi received FDA approval and commercializes FYARRO® for the
treatment of adult patients with locally advanced unresectable or
metastatic malignant perivascular epithelioid cell tumor
(PEComa).
Aadi is exploring nab-sirolimus in PRECISION1, a
Phase 2 tumor-agnostic registration-intended trial in mTOR
inhibitor-naïve malignant solid tumors
harboring TSC1 or TSC2 inactivating
alterations. Aadi is also exploring nab-sirolimus in
two single-indication Phase 2 trials for difficult-to-treat
mTOR-driven cancers: neuroendocrine tumors (NETs), and advanced or
recurrent endometrioid-type endometrial cancer (EEC) in combination
with letrozole. More information on the Company's development
pipeline is available on the Aadi website
at www.aadibio.com and connect with us on Twitter and
LinkedIn.
Contact:
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-first-quarter-2024-results-and-corporate-update-302132110.html
SOURCE Aadi Bioscience